Palisade Bio adds Robert Baltera, Jordan Zwick to board of directors

Palisade Bio

Palisade Bio

PALI

0.00
  • Palisade Bio added Robert Baltera, senior advisor at Frazier Life Sciences, to its board as it advances PALI-2108 toward Phase 2.
  • Baltera previously led Amira Pharmaceuticals as CEO before its 2011 sale to Bristol-Myers Squibb for USD 475 million.
  • Jordan Zwick, co-founder and chief business officer of Mirador Therapeutics, also joined the board.
  • Zwick previously held senior business development and strategy roles at Amarin and InflaRx, with earlier experience at Medtronic.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110845PRIMZONEFULLFEED9745522) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.